Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Basis of Presentation - Additional Information (Detail)

v3.10.0.1
Nature of Business and Basis of Presentation - Additional Information (Detail)
$ in Thousands
3 Months Ended 6 Months Ended
May 23, 2018
Aug. 01, 2017
Jan. 05, 2017
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Nature Of Business And Basis Of Presentation [Line Items]                
Reverse stock split ratio 0.1              
Accumulated deficit       $ (18,504)   $ (18,504)   $ (12,694)
Net loss       (2,788) $ (166) (5,810) $ (371)  
Cash and cash equivalents at carrying value       15,280   15,280   $ 5,284
Working capital       $ 12,800   $ 12,800    
OncoGenex Pharmaceuticals, Inc [Member]                
Nature Of Business And Basis Of Presentation [Line Items]                
Reverse stock split ratio   0.0909 0.0909